Announcements
- Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings
- Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients
- Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
- Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program
- Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial
- Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers
- Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers
- Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments
More ▼
Key statistics
On Thursday, Monopar Therapeutics Inc (1IY:FRA) closed at 0.68, 183.33% above the 52 week low of 0.24 set on Nov 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.68 |
---|---|
High | 0.68 |
Low | 0.68 |
Bid | 0.645 |
Offer | 0.715 |
Previous close | 0.68 |
Average volume | 133.20 |
---|---|
Shares outstanding | 17.45m |
Free float | 8.32m |
P/E (TTM) | -- |
Market cap | 13.09m USD |
EPS (TTM) | -0.612 USD |
Data delayed at least 15 minutes, as of May 09 2024 14:29 BST.
More ▼